Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

One in eight cancers are likely caused by an infection worldwide, new study finds (opens in a new tab)

medicalxpress.com · 2026-09-29

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Two of five claims match the study. This overall rating is based only on the claims we could check. Three claims the study doesn't address.

  • 2 supported
  • 3 not covered
Open claim evidence
3
Source paper

Source layer

The 9 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredThe article says the study was not intended to compare years directly, but to highlight where controlling and preventing infections can reduce cancer rates.View evidenceHide evidence

Why this verdict

The prevention-opportunity framing is supported by the paper’s interpretation, which highlights infection control and prevention interventions. However, the supplied abstract-level profile does not verify the statement that the study was not intended to compare years directly or the specific rationale about changed data sources/quality.

1

Study evidence

Infection control is an important strategy for cancer prevention, as inferred from the estimated number and proportion of cancers attributable to infectious agents.

“Our findings highlight the importance of infection control to achieve cancer prevention.”
Claim 2 of 5Not coveredThe article says many cancers are preventable and gives HPV vaccination as an example, noting that HPV infections have dropped by 90% among eligible people in Australia since 2007 and that Australia could be on track to eliminate cervical cancer by 2035.View evidenceHide evidence

As stated90% drop; eliminate cervical cancer by 2035

Why this verdict

The paper’s abstract-level interpretation supports the general point that infection control, including HPV vaccination, is relevant to cancer prevention. But the specific Australia claims—a 90% drop in HPV infections among eligible people since 2007 and possible cervical-cancer elimination by 2035—are not present in the supplied paper profile, so they cannot be verified at this evidence depth.

1

Study evidence

Infection control is an important strategy for cancer prevention, as inferred from the estimated number and proportion of cancers attributable to infectious agents.

“Our findings highlight the importance of infection control to achieve cancer prevention.”
Claim 3 of 5Not coveredThe article says around 75% of cancers caused by infections were found in low- and middle-income countries.View evidenceHide evidence

As statedaround 75%

Why this verdict

The paper profile says estimates were aggregated by World Bank income group and reports regional variation, but the supplied abstract-level evidence does not provide the claimed figure that around 75% of infection-attributable cancers were in low- and middle-income countries. The direction of an inequitable burden is plausible from the study design, but the specific magnitude is not verifiable here.

1

Study evidence

Estimated 2.3 million new cancer cases globally in 2024 were attributable to infections, equivalent to 12% of all cancer cases.2.3 million; 12% of all cancer cases

“In this worldwide incidence analysis, we used data from the Global Cancer Observatory's Cancer Today (GLOBOCAN) database of cancer incidence in 2024 to estimate population-attributable fractions (PAFs), absolute numbers, and age-standardised incidence rates (ASIRs) of new cancer cases attributable to 12 infectious agents”
Claim 4 of 5SupportedAround 12% of the world's cancer cases in 2024 were likely caused by an infection worldwide, according to new research from the World Health Organization.View evidenceHide evidence

As statedaround 12%

Why this verdict

The abstract-level profile supports the headline figure: the study estimated 2.3 million new cancer cases attributable to infections globally in 2024, equal to 12% of all cancer cases. The paper frames this through population-attributable fractions for IARC Group 1 infectious agents, so the story’s causal/attributable wording is consistent with the paper’s framing.

1

Study evidence

Estimated 2.3 million new cancer cases globally in 2024 were attributable to infections, equivalent to 12% of all cancer cases.2.3 million; 12% of all cancer cases

“In this worldwide incidence analysis, we used data from the Global Cancer Observatory's Cancer Today (GLOBOCAN) database of cancer incidence in 2024 to estimate population-attributable fractions (PAFs), absolute numbers, and age-standardised incidence rates (ASIRs) of new cancer cases attributable to 12 infectious agents”
Claim 5 of 5SupportedThe study linked 2.3 million new cancer cases to an infection, with most caused by Helicobacter pylori, HPV, hepatitis B, Epstein-Barr virus and hepatitis C.View evidenceHide evidence

As stated2.3 million new cancer cases; 4%, 4%, 2%, 1%, and under 1%

Why this verdict

The profile reports 2.3 million infection-attributable new cancer cases and the same leading agents and proportions/counts: H. pylori 4%, HPV 4%, HBV 2%, EBV 1%, and HCV under 1%. These five pathogens account for nearly all of the reported infection-attributable total, so the claim is supported at abstract depth.

1

Study evidence

Estimated 2.3 million new cancer cases globally in 2024 were attributable to infections, equivalent to 12% of all cancer cases.2.3 million; 12% of all cancer cases

“In this worldwide incidence analysis, we used data from the Global Cancer Observatory's Cancer Today (GLOBOCAN) database of cancer incidence in 2024 to estimate population-attributable fractions (PAFs), absolute numbers, and age-standardised incidence rates (ASIRs) of new cancer cases attributable to 12 infectious agents”
2

Study evidence

EBV accounted for an estimated ~260,000 new cancer cases in 2024 (about 1% of all cancer cases globally); a focused analysis reported regional variation in the distribution of EBV-attributable cancer types, though the abstract provides no region-specific breakdowns.

“Focused analysis of EBV-attributable cancers revealed regional variation in the distribution of cancer types.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Study design and inputs: a worldwide incidence analysis using GLOBOCAN Cancer Today 2024, population-attributable fractions, attributable case counts, and ASIRs for 12 IARC Group 1 infectious agents, stratified by sex, country, and age and aggregated by region/income group.

    The story conveys that the paper produced estimates, but it does not materially explain the GLOBOCAN/PAF estimation design, the 12-agent scope, ASIRs, or stratification/aggregation methods.

    From database incidence analysis

  • Regional burden details: eastern Asia had the largest burden, with 990,000 attributable cases and 42% of the global total; ASIRs were above the global average in sub-Saharan Africa, central/eastern Europe, and southeastern Asia.

    The story emphasizes low- and middle-income countries, but the specific regional findings available in the abstract-level profile are not reported.

    From database incidence analysis

  • Focused EBV analysis: EBV accounted for about 260,000 cases and showed regional variation in the distribution of EBV-attributable cancer types.

    The story mentions EBV as one of the five major pathogens but does not reflect the paper’s separate EBV-focused analysis or its finding about regional variation by cancer type.

    From Descriptive, subset/stratified analysis of EBV-attributable cancers

3 things the story did carry across
  • Global 2024 infection-attributable cancer burden: 2.3 million new cases, corresponding to 12% of all cancer cases.
  • Agent-specific burden: H. pylori and HPV each about 4%, HBV 2%, EBV 1%, and HCV under 1% of all cancers, making these the largest contributors among infectious agents.
  • Interpretive prevention and policy implications: infection control is important for cancer prevention; relevant interventions include HPV/HBV vaccination, testing and treatment for HIV, H. pylori, HBV and HCV, safer injection practices, condoms/PrEP, and screening of HPV-driven precancerous lesions.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataQuantify the 2024 global and regional burden of cancer incidence attributable to 12 IARC Group 1 carcinogenic infectious agents using GLOBOCAN 2024, reporting PAFs, absolute case counts, and ASIRs stratified by sex, country, age group, and aggregated by UN subregion and World Bank income group.database incidence analysisExpand

In plain English

Worldwide incidence analysis using GLOBOCAN Cancer Today 2024 to estimate population-attributable fractions (PAFs), attributable case counts, and age-standardised incidence rates (ASIRs) of new cancer cases attributable to 12 IARC Group 1 infectious agents, with outputs stratified by sex, country, and age and aggregated by UN subregion and World Bank income group. Main finding: an estimated 2.3 million infection-attributable new cancer cases in 2024 (12% of all cancer cases), with notable geographic and agent-specific variation.

Key findings

  • Estimated 2.3 million new cancer cases globally in 2024 were attributable to infections, equivalent to 12% of all cancer cases.2.3 million; 12% of all cancer cases
  • Largest numbers of infection-attributable cancers were attributable to H. pylori (760,000 cases; PAF 4%) and HPV (750,000 cases; PAF 4%), followed by HBV (360,000; PAF 2%), EBV (260,000; PAF 1%), and HCV (160,000; <1%).H. pylori 760,000 (PAF 4%); HPV 750,000 (PAF 4%); HBV 360,000 (PAF 2%); EBV 260,000 (PAF 1%); HCV 160,000 (<1%)
“In this worldwide incidence analysis, we used data from the Global Cancer Observatory's Cancer Today (GLOBOCAN) database of cancer incidence in 2024 to estimate population-attributable fractions (PAFs), absolute numbers, and age-standardised incidence rates (ASIRs) of new cancer cases attributable to 12 infectious agents”
2secondary dataProvide a focused analysis of EBV-attributable cancers, emphasizing regional variation in the distribution of EBV-attributable cancer types.Descriptive, subset/stratified analysis of EBV-attributable cancersExpand

In plain English

The paper presents a focused, descriptive analysis of cancers attributable to Epstein-Barr virus (EBV) using the GLOBOCAN 2024 incidence estimates and the study's population-attributable fraction approach; it reports that EBV-attributable cancers numbered ~260,000 new cases in 2024 (≈1% of all cancers) and states that the distribution of EBV-attributable cancer types varies by region, without giving detailed regional breakdowns in the abstract.

Key findings

  • EBV accounted for an estimated ~260,000 new cancer cases in 2024 (about 1% of all cancer cases globally); a focused analysis reported regional variation in the distribution of EBV-attributable cancer types, though the abstract provides no region-specific breakdowns.
“Focused analysis of EBV-attributable cancers revealed regional variation in the distribution of cancer types.”
What this piece can’t prove
  • Reliance on secondary GLOBOCAN data and PAF calculations may inherit limitations of those inputs (e.g., variation in cancer registry coverage, quality of etiologic attribution), but the abstract does not allow assessment of these issues for the EBV-focused analysis.

2 further details could not be confirmed from the summary.

3otherInterpret results for prevention and policy, highlighting infection-control interventions (eg, HPV/HBV vaccination, testing/treatment for HIV/H pylori/HBV/HCV, safer injection, condoms/PrEP, screening for HPV-driven lesions) and implications for R&D investment (notably EBV).Narrative interpretationExpand

In plain English

The authors interpret their 2024 GLOBOCAN-derived estimates of cancers attributable to infectious agents to recommend infection-control measures and to motivate research investment. They state infection control is key to cancer prevention and list specific, evidence-based but underused interventions (HPV and HBV vaccination; testing and treatment for HIV, Helicobacter pylori, HBV, and HCV; safe injection practices; condoms and pre-exposure prophylaxis to prevent HIV transmission; and screening of precancerous lesions for HPV-driven cervical and anal cancer). They also argue the results support investment in new prevention tools, most notably for Epstein-Barr virus (EBV). These statements are presented as interpretive policy and prevention implications rather than new primary analyses.

Key findings

  • Infection control is an important strategy for cancer prevention, as inferred from the estimated number and proportion of cancers attributable to infectious agents.
  • Scientifically supported but often underused interventions recommended include HPV and HBV vaccination; testing and treatment for HIV, H. pylori, HBV, and HCV; safe injection practices; access to condoms and pre-exposure prophylaxis to prevent HIV transmission; and screening of precancerous lesions for HPV-driven cervical and anal cancer.
“Our findings highlight the importance of infection control to achieve cancer prevention.”
What this piece can’t prove
  • This appraisal unit contains narrative interpretation and policy recommendations rather than new primary analyses.
  • No assessment of implementation feasibility, cost-effectiveness, or programmatic barriers for the recommended interventions is provided here.
  • Recommendations rely on GLOBOCAN 2024 attributable-burden estimates; uncertainties or methodological limitations of those underlying estimates are not detailed in this interpretive section.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 22 candidate papers

And 16 more candidates considered.